Autolus Therapeutics
Autolus Therapeutics is a clinical-stage biopharmaceutical company developing next-generation CAR T cell therapies for patients with cancer and autoimmune diseases.
No open positions right now. Check back soon!
Browse all jobsAbout the company
Autolus Therapeutics is a clinical-stage biopharmaceutical company developing next-generation CAR T cell therapies for patients with cancer and autoimmune diseases. The company applies advanced cell programming and proprietary manufacturing processes to engineer a patient's T cells, with a pipeline spanning hematological malignancies, solid tumors, and autoimmune indications. Autolus is building a fully integrated CAR T company, from research and development through manufacturing and commercialization.
Autolus has a growing presence in Spain, with open roles in engineering, quality, operations, and business development. The company's work culture emphasizes flexibility, diversity, and teamwork, and it offers opportunities for international professionals in a dynamic biotech environment. As a clinical-stage company, roles in Spain span both technical and strategic functions, supporting the company's mission to deliver life-changing therapies.
For International Professionals
- Autolus is a clinical-stage biopharmaceutical company, so roles in Spain may involve working on cutting-edge CAR T cell therapies.
- The company has a fully integrated model, meaning opportunities span R&D, manufacturing, quality, and commercial functions.
- Autolus emphasizes a flexible, diverse, and dynamic working environment, which may appeal to international professionals.
- Spain-based roles include engineering, quality assurance, and business development, indicating a broad range of functions.
- The company is publicly listed (NASDAQ: AUTL), providing transparency into its financial and operational status.
Company History
Autolus Therapeutics is a clinical-stage biopharmaceutical company developing next-generation CAR T cell therapies for cancer and autoimmune diseases. The company was founded in 2014 as a spin-out from University College London, and is now building a fully integrated CAR T company with a pipeline including obecabtagene autoleucel (obe-cel) for adult acute lymphoblastic leukemia.